Vertex Pharmaceuticals VRTX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's operating cash flow?
- Vertex Pharmaceuticals (VRTX) reported operating cash flow of $1.43B in Q1 2026.
- How has Vertex Pharmaceuticals's operating cash flow changed year-over-year?
- Vertex Pharmaceuticals's operating cash flow increased by 74.4% year-over-year, from $818.9M to $1.43B.
- What is the long-term trend for Vertex Pharmaceuticals's operating cash flow?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's operating cash flow has grown at a 6.3% compound annual growth rate (CAGR), from $2.84B to $3.63B.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.